A message from our partners at Huge Alerts 
BioStem Technologies (BSEM) Rockets Toward Nasdaq with Record Earnings, Transformational $40M Acquisition, and High-Margin Growth Signaling a $25.50 Upside! BioStem Technologies, Inc. (OTCQB: BSEM) is turning heads in the regenerative medicine space with seven consecutive profitable quarters, blockbuster gross margins hitting 97%, and a bold $40 million acquisition of BioTissue Holdings’ surgical and wound care business. This move instantly expands BSEM’s footprint into higher-acuity care—hospitals, outpatient centers, and ambulatory surgery facilities—while adding established products like Neox® and Clarix®. The acquisition contributes nearly $29 million in revenue from 2025 alone, diversifying the company’s revenue streams and positioning it for a major growth phase in 2026. Beyond strategic expansion, BSEM continues to deliver robust earnings performance. Despite transitional macro pressures and one-time GAAP adjustments, quarterly revenue reached $10.1 million, adjusted EBITDA stayed positive at $3.4 million, and cash remained strong at ~$16 million post-acquisition. With Nasdaq uplisting preparations well underway, including audited 2024–2025 financials and KPMG review, the company is primed to attract institutional investors, improve liquidity, and unlock higher valuation multiples. Analysts see upside to $25.50, highlighting BSEM’s rare combination of profitability, clinical validation, and now expanded commercial reach. Learn why BSEM is on the fast track to becoming a small-cap MedTech standout!
More Reading from MarketBeat Media When Insider Selling Is a Good Thing: 2 Stocks to WatchAuthored by Thomas Hughes. Originally Published: 3/23/2026. 
Key Points - Waste Management insiders sold roughly $25 million in stock after shares hit an all-time high in early 2026, but institutional accumulation and a growing dividend keep the long-term outlook bullish.
- Ionis Pharmaceuticals faces heavier insider and institutional selling, though analysts see roughly 25% upside driven by the commercial ramp of Olezarsen.
- Both stocks have pulled back from recent highs, potentially creating entry points for investors willing to look past short-term selling pressure.
- Special Report: Elon Musk already made me a "wealthy man"
 Insider selling can be constructive when insiders are taking profits in stocks with increasingly bullish outlooks. Here, one name is a cash-generating dividend-growth machine and the other is a commercial-stage biopharma with double-digit — nearly hyper-growth — prospects. In both cases, these stocks have pulled back from early-2026 highs partly because of insider selling, creating potential entry points for new investors. Waste Management Doesn't Waste Time: Growth and Dividends in 2026 Waste Management (NYSE: WM) rallied about 25% from its 2025 low to reach a new all-time high in early 2026. That peak prompted several insiders — including the CEO, CFO, CAO, COO and multiple VPs — to sell shares. The sales helped cap gains in Q1 but are otherwise immaterial to the longer-term outlook: insiders hold only about 0.18% of the stock, and total insider sales were under $25 million, while other factors remain broadly bullish for the name. Institutional activity shows accumulation over the trailing 12 months, with buying ramping in 2025 and remaining strong in 2026. Institutions own roughly 80% of outstanding shares and, notably, have been net buyers for three years with no distribution quarters. Earnings and capital return plans suggest this accumulation trend may continue. Analysts are also bullish, with 25 tracked ratings for 2026 and growing coverage. That support provides a price tailwind and an incentive for investors to consider the stock. Market sentiment is firming: the Moderate Buy rating is edging toward Strong Buy, and price targets are trending upward. Consensus models imply roughly 10% upside as of late March, but analyst movement toward higher targets increases the likelihood of a new all-time high. 
The dividend is another reason to own the stock. Waste Management yields about 1.65% in early 2026, with a payout ratio near 56% of earnings and a track record of annual increases. If current trends continue, the company could be on track for inclusion in the Dividend Aristocrats Index by the end of the decade — a development likely to attract more long-term buy-and-hold ownership, reduce volatility and support the stock-price uptrend. Ionis Pharmaceuticals: A Cautious Outlook for a Potential Blockbuster Ionis Pharmaceuticals (NASDAQ: IONS) is an RNA-focused biopharma with multiple commercial products and two drivers that matter most. Spinraza, sold through a partner, has delivered blockbuster sales but is in decline. Olezarsen, wholly owned by Ionis, is projected to reach peak sales above $2 billion — a figure many analysts consider conservative, which has lifted price targets. Insider selling at Ionis resembles Waste Management's pattern in Q1 2026, but here insiders also sold heavily in 2025 and institutional selling has been meaningful. Institutions own more than 90% of the shares and were net sellers in three of four quarters in 2025, continuing at a fast pace in Q1 2026 as they took profits. Analysts largely offset that activity. Institutions likely trimmed positions after the stock more than doubled from its 2025 low, but analyst coverage paints a different picture: a consensus Moderate Buy from 21 analysts, expanding coverage, firmer sentiment and rising price targets. The consensus implies roughly 25% upside by year-end, and the high end of analyst targets adds another ~10% beyond that. 
Ionis' growth outlook is the primary reason to own the stock. The company is forecast to sustain high-20% growth into the next decade, reach profitability in 2028 and improve margins thereafter. Based on current long-range forecasts, the stock could trade at roughly 7x projected 2035 earnings — implying the potential for substantial upside; it could more than double and still appear reasonably valued. If Olezarsen's forecasts prove conservative and the pipeline delivers, the upside could be materially higher. Ionis has multiple candidates progressing toward near- and mid-term commercialization. | 
0 Response to "BioStem targets Nasdaq uplisting after 7 straight profitable quarters"
Post a Comment